In Brief: Astra Merck
Executive Summary
Astra Merck: Nancy Wysenski to VP-sales and Barry Greene to VP-marketing and customer services, filling roles vacated by VP-Sales and Marketing Matthew Emmens. Emmens was named acting CEO Jan. 17, replacing Wayne Yetter, who departed to lead Novartis' U.S. pharmaceuticals business ("The Pink Sheet" Feb. 3, T&G-1). Wysenski was executive director of field sales at Astra Merck; Greene had worked on process design for Astra Merck's sales and marketing organization as an associate partner with Andersen Consulting. Astra Merck also announces the promotions of VP-Drug Development Irwin Scher to chief medical officer and senior VP-drug development; VP-Portfolio Management Dave Brennan to senior VP-business operations; and Rob Cohen, VP-information technology, to chief information officer...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth